24 November 2017
News and Views
Links and Services
The latest Alimentary Pharmacology & Therapeutics investigates the impact of crossing over from placebo to rifaximin treatment on breakthrough hepatic encephalopathy.
Rifaximin therapy reduced risk of hepatic encephalopathy recurrence and hepatic encephalopathy-re
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors